Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Overview of attention for article published in Cardiovascular Diabetology, January 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 30 X posts from 29 X users, with an upper bound of 43,630 followers.

RT @mendez_bailon: Empagliflozina mejora los parametros de disfuncion diastolica y mitocondrial. #diabetes @IcaSemes @UMIPIC https://t.co/…

RT @mendez_bailon: Empagliflozina mejora los parametros de disfuncion diastolica y mitocondrial. #diabetes @IcaSemes @UMIPIC https://t.co/…

RT @mendez_bailon: Empagliflozina mejora los parametros de disfuncion diastolica y mitocondrial. #diabetes @IcaSemes @UMIPIC https://t.co/…

RT @mendez_bailon: Empagliflozina mejora los parametros de disfuncion diastolica y mitocondrial. #diabetes @IcaSemes @UMIPIC https://t.co/…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 26 additional X posts.